A hierarchical and configurational analysis of Health Technology Assessment outcomes for cell and gene therapies
HTA success for CGTs is not determined by isolated attributes but by the strategic alignment of therapy-level evidence, agency-level processes, and country-level context. The influence of organized patient advocacy and the structural flexibility of HTA systems are critical, previously under-quantified components of this alignment.
Authors
- Saja Almazrou (ORCID: https://orcid.org/0000-0002-9307-2913)
- Nehad J. Ahmed (ORCID: https://orcid.org/0000-0003-4215-6225)
- Ziyad S. Almalki (ORCID: https://orcid.org/0000-0003-1618-4142)
- Abdullah K. Alahmari (ORCID: https://orcid.org/0000-0002-1047-6913)
- Mouaddh Abdulmalik Nagi (ORCID: https://orcid.org/0000-0003-4976-0978)
- Areej Alshlowi
- Syeda Juweria
- Yazan M. Alzahrani
- Moayad Alhamdani
- Renad M. Alshammari
- Nadia A. Dahduli
Institutions
- Alfaisal University (SA)
- Prince Sattam Bin Abdulaziz University (SA)
- King Saud University (SA)
- Aljanad University for Science and Technology
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.3389/fphar.2025.1695961
- Primary Topic
- Biomedical Ethics and Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Prince Sattam bin Abdulaziz University